Skip to main navigation
Skip to search
Skip to main content
The University of Brighton Home
Home
Profiles
Research units
Equipment
Projects
Research output
Activities
Student theses
Search by expertise, name or affiliation
Hypoxia as a target for drug combination therapy of liver cancer
Cressida Bowyer
, Andrew Lewis
,
Andrew Lloyd
, Gary Phillips
,
Wendy Macfarlane
University of Brighton
Centre for Regenerative Medicine and Devices
Centre for Lifelong Health
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Profiles
(2)
Fingerprint
Dive into the research topics of 'Hypoxia as a target for drug combination therapy of liver cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Hypoxia
100%
Doxorubicin
100%
Liver Cancer
100%
Drug Combination Therapy
100%
Hypoxia-inducible factor-1α (HIF-1α)
66%
Hepatocellular Carcinoma
50%
Rapamycin
50%
Improved Outcomes
33%
HepG2 Cells
33%
Normoxic
33%
Standard of Care
16%
Murine Model
16%
Transcription Factor
16%
Transarterial Chemoembolization
16%
Western Blotting
16%
Locoregional Drug Delivery
16%
Drug-eluting Beads
16%
Cancer Cells
16%
Drug Combination
16%
Antitumor Effect
16%
Anticancer
16%
Hypoxic Condition
16%
Hypoxia Response
16%
Combination Treatment
16%
Hepatocellular Carcinoma Treatment
16%
Lowest Effective Dose
16%
Doxorubicin Treatments
16%
Tumor Emboli
16%
MTOR Inhibitor
16%
Xenograft
16%
Intermediate-stage Hepatocellular Carcinoma
16%
Chemoresistant
16%
Normoxic Conditions
16%
Hypoxic Cells
16%
Combined Drug Therapy
16%
Embolization Procedures
16%
Cancer Mortality
16%
Pharmacology, Toxicology and Pharmaceutical Science
Hypoxia
100%
Doxorubicin
100%
Combination Therapy
100%
Liver Cancer
100%
Combination Drug
100%
Liver Cell Carcinoma
71%
Hypoxia Inducible Factor 1
57%
Rapamycin
42%
Malignant Neoplasm
28%
Western Blot
14%
Transcription Factors
14%
Neoplasm
14%
Pharmacotherapy
14%
Cancer Mortality
14%